NewAmsterdam Pharma Company (NAMS) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

NewAmsterdam Pharma Company (NAMS) Company Statistics | The Fly

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

NewAmsterdam Pharma Company

· NAMS

Dashboard

Financials

Ratios

Valuation

Statistics

2.685 B

-3.19%

General

Market Cap: $2.77B
Enterprise Value: $2.2B
Shares Outstanding: 116,900,000
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: 92.15%
Operating Margin: -3432.20%
Net Profit Margin: -3644.21%
FCF Margin: -2018.28%
ROA: -36.84%
ROE: -38.33%
ROIC: -38.70%
Current Ratio: 9.03
Debt-to-Equity: 0.00
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: -0.32
P/S: 368.89
P/FCF: —
P/B: 4.16
EV/EBITDA: -8.64

Growth

Rev 1Y: -50.61%
Rev 1Y Fwd Est: 34.49%
Rev 3Y (CAGR): —
Rev 5Y (CAGR): —
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —
EPS 5Y (CAGR)

Income Statement (TTM)

Revenue: $7.12M
Gross Margin: 92.15%
Operating Expenses: $250.97M
Operating Income: -$244.41M
Net Profit: -$259.5M

Balance Sheet

—

EPS 10Y (CAGR)

—

Cash and Equivalents: $424.15M
Working Capital: $586.23M
Total Assets: $704.45M
Net Debt: -$424.07M
Total Liabilities: $73.03M
Total Equity: $631.42M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$143.46M
Cash Flow from Investing: -$34.91M
Cash Flow from Financing: $41.68M
Free Cash Flow: -$143.72M
Capital Expenditures: $260K